Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| DL3-H82F5 | Human | Biotinylated Human DLL3 Protein, Fc,Avitag™ |  |
||
| DL3-H82E4 | Human | Biotinylated Human DLL3 Protein, His,Avitag™ |  |
||
| DL3-R52H4 | Rhesus macaque | Rhesus macaque DLL3 Protein, His Tag |  |
||
| DL3-M52H3 | Mouse | Mouse DLL3 Protein, His Tag |  |
||
| DL3-R52H3 | Rat | Rat DLL3 Protein, His Tag |  |
||
| DL3-HF2H4 | Human | FITC-Labeled Human DLL3 Protein, His Tag |  |
|
|
| DL3-HF253 | Human | FITC-Labeled Human DLL3 Protein, Fc Tag |  |
|
|
| DL3-C52H3 | Cynomolgus | Cynomolgus DLL3 Protein, His Tag |  |
|
|
| DL3-H52H4 | Human | Human DLL3 Protein, His Tag (MALS verified) |  |
|
|
| DL3-H5255 | Human | Human DLL3 Protein, Fc Tag (MALS verified) |  |
|
|
Immobilized Anti-DLL3 Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human DLL3, Fc Tag (Cat. No. DL3-HF253) with a linear range of 0.01-0.313 μg/mL (QC tested).
The purity of Human DLL3, His Tag(Cat. No. DL3-H52H4) was more than 95% and the molecular weight of this protein is around 55-75 kDa verified by SEC-MALS.
Immobilized Human DLL3, His Tag (Cat. No. DL3-H52H4) at 1 μg/mL (100 μL/well) can bind Anti-DLL3 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| 89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
| Rovalpituzumab tesirine | SC-0002; SC0001SCX; SC16LD6.5; SC0001-SCX; P256HB60FF | Phase 3 Clinical | Stemcentrx, Abbvie Inc | Solid tumours; Small Cell Lung Carcinoma; Glioblastoma; Medullary thyroid cancer (MTC); Prostatic Neoplasms; Carcinoma, Neuroendocrine; Melanoma | Details |
| HPN-328 | HPN-328 | Phase 2 Clinical | Harpoon Therapeutics | Small Cell Lung Carcinoma | Details |
| Tarlatamab | AMG-757 | Phase 1 Clinical | Amgen Inc | Small Cell Lung Carcinoma; Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z